Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
NEW YORK, June 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Introduction
The report provides an in-depth analysis of the respiratory franchise. It also Highlights the key R&D trends that may influence treatment sales and includes a thorough analysis of the competitive dynamics of leading brands within each indication, enabling the reader to identify growth of the leading brands, key drug classes and leading players through 2016.
Features and benefits
* Quantify patient potential and assess treatment trends and sales patterns across the major respiratory indications in the seven major markets.
* Discover which indications have the greatest potential to provide growth and understand the growth drivers of the major drug classes.
* Analyse the respiratory franchises of top pharmaceutical companies across major indications, and evaluate the market share of these companies.
* Gain comprehensive understanding of how recent events are affecting the performance of major products and companies.
* Forecast sales of the leading products as well as key pipeline products in the respiratory market over the period 2010–16.
Highlights
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment.
Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical companies, with an estimated 300 compounds in various stages of development. The COPD and allergic rhinitis pipelines are of lesser strength, comprising around 140 products.
Among several once-daily LABA/LAMA combinations in development, Boehringer Ingelheim's BI1744/Spiriva is at an advantage as this combination product uses the current gold standard COPD treatment Spiriva. Other promising Phase III compounds in development include: Novartis's NVA237 (glycopyrrolate) and GSK's 642444 (vilanterol trifenatate). Novart
Your key questions answered
* What will be the major growth indications and the accompanying growth drivers in the global respiratory market over the period to 2016?
* Which companies have the strongest respiratory portfolios and ?
* What are the promising compounds in clinical development for major respiratory indications, and what is their forecast commercial potential?
* What are the current trends within the major therapy areas such as asthma/COPD and allergic rhinitis across the seven major markets?
* What are the recent regulatory changes in the respiratory arena and what will be their impact on the marketed products?
Executive Summary
Overview and epidemiology of respiratory disorders
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of respiratory disorders
Summary
Introduction
Asthma
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
COPD
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Allergic rhinitis
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Introduction
Key events in the global respiratory market
New FDA recommendations state that LABAs cannot be used as monotherapy
FDA requires new outcomes studies for currently approved LABAs in asthma
FDA: inhalers that contain CFCs to be phased out in US
Merck's Dulera (formoterol/mometasone) approved by the FDA for asthma
Forest/Nycomed's Daxas approved in EU for severe COPD
SkyePharma's NDA for Flutiform rejected by FDA
Novartis's Xolair rejected by NICE for pediatric asthma
AstraZeneca launched Symbicort in Japan
GSK and Mitsubishi Tanabe ended Japanese tie-up for co-promotion of Adoair
Leading respiratory brands
Seretide
Singulair
Spiriva
Symbicort
Nasonex
Pulmicort
Flixotide
Combivent
Ventolin
Allegra
Market analysis by drug class
Drug class analysis
Asthma/COPD drugs
Allergic rhinitis drugs
Respiratory sales forecast to 2016
Pipeline analysis
Summary
Introduction
Key R&D events
GSK dropped darotropium from its COPD pipeline
Spiriva's safety review reveals that the drug was not associated with CV risk
Global respiratory pipeline
Leading drugs in development
Profiles of key pipeline products
Recently launched compounds
New drug application filed
Phase III compounds
Phase II compounds
Pipeline forecasts
Competitive landscape
Summary
Introduction
GSK
Merck & Co.
Boehringer Ingelheim
AstraZeneca
Novartis
Appendix
Scope
Methodology
Market size methodology
Epidemiology
Market forecast
References
Prevalence of asthma
Prevalence of COPD
Prevalence of allergic rhinitis
Abbreviations
To order this report:
Pathology Industry: The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article